Infinity Pharmaceuticals traded at $0.0001 this Thursday February 19th. Looking back, over the last four weeks, Infinity Pharmaceuticals lost 0 percent. Over the last 12 months, its price rose by 900.00 percent. Looking ahead, we forecast Infinity Pharmaceuticals to be priced at 0.0001 by the end of this quarter and at 0.0001 in one year, according to Trading Economics global macro models projections and analysts expectations.
Infinity Pharmaceuticals, Inc., incorporated on May 11, 2000, Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for people with cancer. It is also focusing on advancing, eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its pipeline includes MARIO-275 is, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line setting for triple negative breast cancer (TNBC), and front-line renal cell carcinoma (RCC). MARIO-1 is in Phase I /1b clinical study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity for eganelisib.